128
Views
0
CrossRef citations to date
0
Altmetric
Original Research

New Perspective to Improve Care of Patients with Infected Diabetic Foot Ulcer: Early Economic Impact of the Use of Photodynamic Therapy with RLP068 (Based) System

, , , ORCID Icon, , , & show all
Pages 135-144 | Published online: 26 Feb 2021

References

  • Federation ID. IDF Diabetes Atlas Eighth edition 2017. International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium: International Diabetes Federation; 2017. Available from: http://www.diabetesatlas.org. Accessed January 18, 2021.
  • Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376(24):2367–2375. doi:10.1056/NEJMra1615439
  • Yazdanpanah L, Shahbazian H, Nazari I, et al. Incidence and risk factors of diabetic foot ulcer: a population-based diabetic foot cohort (ADFC study)-two-year follow-up study. Int J Endocrinol. 2018;2018:1–9. doi:10.1155/2018/7631659
  • (No Title) [Internet]. [cited November 5, 2019]. Available from: https://www.istat.it/it/files//2019/09/La-salute-nelle-regioni-italiane.pdf. Accessed January 18, 2021.
  • Diabetic Foot Ulcer (DFU) Treatment Market Size | Industry Report 2025 [Internet]. [cited November 5, 2019]. Available from: https://www.grandviewresearch.com/industry-analysis/diabetic-foot-ulcer-dfu-treatment-market. Accessed January 18, 2021.
  • Prompers L, Huijberts M, Apelqvist J, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia. 2007;50:18–25. doi:10.1007/s00125-006-0491-1
  • Prompers L, Schaper N, Apelqvist J, et al. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetologia. 2008;51(5):747–755. doi:10.1007/s00125-008-0940-0
  • Prompers L, Huijberts M, Schaper N, et al. Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale Study. Diabetologia. 2008;51(10):1826–1834. doi:10.1007/s00125-008-1089-6
  • Yang W, Dall TM, Beronjia K, et al. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917–928.
  • Doubova SV, Borja-Aburto VH, Guerra-Y-Guerra G, Salgado-de-Snyder VN, González-Block MÁ. Loss of job-related right to healthcare is associated with reduced quality and clinical outcomes of diabetic patients in Mexico. Int J Qual Health Care. 2018;30(4):283–290. doi:10.1093/intqhc/mzy012
  • Goodridge D, Trepman E, Sloan J, et al. Quality of life of adults with unhealed and healed diabetic foot ulcers. Foot Ankle Int. 2006;27(4):274–280. doi:10.1177/107110070602700408
  • Ribu L, Wahl A. Living with diabetic foot ulcers: a life of fear, restrictions, and pain. Ostomy Wound Manage. 2004;50(2):57–67.
  • Martínez-Gómez DA, Moreno-Carrillo MA, Campillo-Soto A, Carrillo-García A, Aguayo-Albasini JL. Reduction in diabetic amputations over 15 years in a defined Spain population. Benefits of a critical pathway approach and multidisciplinary team work. Rev Esp Quimioter. 2014;27(3):170–179.
  • Position document Local management of diabetic foot ulcers - Wounds International [Internet]. [cited November 5, 2019]. Available from: https://www.woundsinternational.com/resources/details/position-document-local-management-diabetic-foot-ulcers. Accessed January 18, 2021.
  • IWGDF Guidelines on the prevention and management of diabetic foot disease IWGDF Guidelines [Internet]. [cited November 5, 2019]. Available from: www.iwgdfguidelines.org. Accessed January 18, 2021.
  • Wainwright M, Maisch T, Nonell S, et al. Photoantimicrobials—are we afraid of the light? Lancet Infect Dis. 2017;17(2):e49–e55. doi:10.1016/S1473-3099(16)30268-7
  • Mannucci E, Genovese S, Monami M, et al. Photodynamic topical antimicrobial therapy for infected foot ulcers in patients with diabetes: a randomized, double-blind, placebo-controlled study - The D.A.N.T.E (Diabetic ulcer Antimicrobial New Topical treatment Evaluation) study. Acta Diabetol. 2014;51(3):435–440. doi:10.1007/s00592-013-0533-3
  • Giuliani F, Martinelli M, Cocchi A, Arbia D, Fantetti L, Roncucci G. In vitro resistance selection studies of RLP068/Cl, a new Zn(II) phthalocyanine suitable for antimicrobial photodynamic therapy. Antimicrob Agents Chemother. 2010;54(2):637–642. doi:10.1128/AAC.00603-09
  • Vassena C, Fenu S, Giuliani F, et al. Photodynamic antibacterial and antibiofilm activity of RLP068/Cl against Staphylococcus aureus and Pseudomonas aeruginosa forming biofilms on prosthetic material. Int J Antimicrob Agents. 2014;44(1):47–55. doi:10.1016/j.ijantimicag.2014.03.012
  • Monami M, Scatena A, Schlecht M, et al. Antimicrobial photodynamic therapy in infected diabetic foot ulcers: a multicenter preliminary experience. J Am Podiatr Med Assoc. 2020;110. doi:10.7547/18-069
  • Mosti G, Picerni P, Licau M, Mattaliano V. Photodynamic therapy in infected venous and mixed leg ulcers: a pilot experience. J Wound Care. 2018;27(12):816–821. doi:10.12968/jowc.2018.27.12.816
  • Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system: the contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care. 1998;21(5):855–859. doi:10.2337/diacare.21.5.855
  • Pantò F, Adamo L, Giordano C, Licciardello C. Efficacy and safety of photodynamic therapy with RLP068 for diabetic foot ulcers: a review of the literature and clinical experience. Drugs Context. 2020;9. doi:10.7573/dic.2019-10-3
  • Italian Ministry of Health. Remunerazione prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. Gazzetta Ufficiale - Serie Generale; 2013.
  • Fattore G. Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. PharmacoEconomics. 2009.
  • Piaggesi A, Låuchli S, Bassetto F, et al. Advanced therapies in wound management: cell and tissue based therapies, physical and bio-physical therapies smart and IT based technologies. J Wound Care. 2018;27(Sup6a):S1–137.
  • Chow I, Lemos EV, Einarson TR. Management and prevention of diabetic foot ulcers and infections: a health economic review. PharmacoEconomics. 2008;26(12):1019–1035. doi:10.2165/0019053-200826120-00005
  • Kerr M, Rayman G, Jeffcoate WJ. Cost of diabetic foot disease to the National Health Service in England. Diabet Med. 2014;31(12):1498–1504. doi:10.1111/dme.12545
  • Tchero H, Kangambega P, Lin L, et al. Cost of diabetic foot in France, Spain, Italy, Germany and United Kingdom: a systematic review. Ann Endocrinol (Paris). 2018;79(2):67–74. doi:10.1016/j.ando.2017.11.005
  • Martinelli N, Curci V, Quarantiello A, Saldalamacchia G. The benefits of antimicrobial photodynamic therapy with RLP068 in the management of diabetic foot ulcers. Drugs Context. 2019;8:1–8. doi:10.7573/dic.212610